|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2019
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L04AC19
|
|
gptkbp:chemicalClass
|
humanized monoclonal antibody
|
|
gptkbp:developedBy
|
gptkb:Boehringer_Ingelheim
gptkb:AbbVie
|
|
gptkbp:drugClass
|
gptkb:monoclonal_antibody
|
|
gptkbp:form
|
solution for injection
pre-filled pen
pre-filled syringe
|
|
gptkbp:genericName
|
gptkb:risankizumab
|
|
gptkbp:halfLife
|
about 28 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Skyrizi
|
|
gptkbp:indication
|
gptkb:Crohn's_disease
gptkb:psoriatic_arthritis
plaque psoriasis
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedIn
|
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
IL-23 inhibitor
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:prescriptionRequired
|
https://www.skyrizi.com/
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
fatigue
headache
injection site reactions
upper respiratory tract infection
|
|
gptkbp:target
|
interleukin-23 p19 subunit
|
|
gptkbp:bfsParent
|
gptkb:AbbVie
|
|
gptkbp:bfsLayer
|
6
|